Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation Pharmaceutical Investing
Can-Fite Announces Enrollment of First Patient in its Comfort Phase III Trial of Piclidenoson in Psoriasis Biotech Investing
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias Pharmaceutical Investing
European Medicines Agency Authorizes Deferral of Paediatric Investigation Plan for Trogarzo Pharmaceutical Investing
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation Biotech Investing
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients Pharmaceutical Investing
ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia Pharmaceutical Investing
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials Biotech Investing
Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector Pharmaceutical Investing
